Reported 1 day ago
Eli Lilly and Company has partnered with Rznomics to develop RNA-based therapies for sensorineural hearing loss, with milestone payments exceeding $1.3 billion. Rznomics will focus on early research while Lilly handles clinical development and commercialization. This collaboration complements Lilly's existing gene therapy efforts targeting hearing loss, including a promising therapy aimed at OTOF gene mutations. Industry interest in genetic hearing loss is growing, with recent studies showing significant improvements in hearing for pediatric patients.
Source: YAHOO